Cargando…

Roflumilast Powders for Chronic Obstructive Pulmonary Disease: Formulation Design and the Influence of Device, Inhalation Flow Rate, and Storage Relative Humidity on Aerosolization

Roflumilast is currently administered orally to control acute exacerbations in chronic obstructive pulmonary disease (COPD). However, side effects such as gastrointestinal disturbance and weight loss have limited its application. This work aimed to develop an inhalable roflumilast formulation to red...

Descripción completa

Detalles Bibliográficos
Autores principales:	Momin, Mohammad A. M., Adhikari, Bishal Raj, Sinha, Shubhra, Larson, Ian, Das, Shyamal C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400286/ https://www.ncbi.nlm.nih.gov/pubmed/34452215 http://dx.doi.org/10.3390/pharmaceutics13081254

Ejemplares similares

Amorphicity and Aerosolization of Soluplus-Based Inhalable Spray Dried Powders
por: Adhikari, Bishal Raj, et al.
Publicado: (2022)

Inhalable Combination Powder Formulations for Treating Latent and Multidrug-Resistant Tuberculosis: Formulation and In Vitro Characterization
por: Eedara, Basanth Babu, et al.
Publicado: (2023)

Inhalable Dry Powder of Bedaquiline for Pulmonary Tuberculosis: In Vitro Physicochemical Characterization, Antimicrobial Activity and Safety Studies
por: Momin, Mohammad A. M., et al.
Publicado: (2019)

Manipulation of Spray-Drying Conditions to Develop an Inhalable Ivermectin Dry Powder
por: Saha, Tushar, et al.
Publicado: (2022)

Co-Amorphization of Kanamycin with Amino Acids Improves Aerosolization
por: Adhikari, Bishal Raj, et al.
Publicado: (2020)

Inhalable Formulation Based on Lipid–Polymer Hybrid Nanoparticles for the Macrophage Targeted Delivery of Roflumilast
por: Craparo, Emanuela F., et al.
Publicado: (2022)

State of the Art in Capsule-Based Dry Powder Inhalers: Deagglomeration Techniques and the Consequences for Formulation Aerosolization
por: Groß, Roman, et al.
Publicado: (2022)

Impact of Leucine and Magnesium Stearate on the Physicochemical Properties and Aerosolization Behavior of Wet Milled Inhalable Ibuprofen Microparticles for Developing Dry Powder Inhaler Formulation
por: Sharif, Shahjabeen, et al.
Publicado: (2023)

An aerosol formulation of R-salbutamol sulfate for pulmonary inhalation
por: Zhang, Xuemei, et al.
Publicado: (2014)

Spray-Dried Inhalable Microparticles Combining Remdesivir and Ebselen against SARS-CoV-2 Infection
por: Saha, Tushar, et al.
Publicado: (2023)

Inhaled therapy for COVID-19: Considerations of drugs, formulations and devices
por: Saha, Tushar, et al.
Publicado: (2022)

Radiolabeling Method for Lyophilizate for Dry Powder Inhalation Formulations
por: Miyamoto, Kahori, et al.
Publicado: (2022)

Pulmonary availability of isotretinoin in rats after inhalation of a powder aerosol
por: Raleigh, S M, et al.
Publicado: (2000)

Difference in resistance to humidity between commonly used dry powder inhalers: an in vitro study
por: Janson, Christer, et al.
Publicado: (2016)

Dispersibility and Storage Stability Optimization of High Dose Isoniazid Dry Powder Inhalation Formulations with L-Leucine or Trileucine
por: Sibum, Imco, et al.
Publicado: (2019)

Characterization and Formulation of Isoniazid for High-Dose Dry Powder Inhalation
por: Sibum, Imco, et al.
Publicado: (2019)

Spray Dried Formulations for Inhalation—Meaningful Characterisation of Powder Properties
por: Jüptner, Angelika, et al.
Publicado: (2019)

Simultaneous Spray Drying for Combination Dry Powder Inhaler Formulations
por: Shepard, Kimberly B., et al.
Publicado: (2022)

A review of formulations and preclinical studies of inhaled rifampicin for its clinical translation
por: Khadka, Prakash, et al.
Publicado: (2022)

Inhalable PEGylated Phospholipid Nanocarriers and PEGylated Therapeutics for Respiratory Delivery as Aerosolized Colloidal Dispersions and Dry Powder Inhalers
por: Muralidharan, Priya, et al.
Publicado: (2014)

Risk factors for the discontinuation of roflumilast in patients with chronic obstructive pulmonary disease
por: Kim, Kyung Hoon, et al.
Publicado: (2017)

Effect and safety of roflumilast for chronic obstructive pulmonary disease in Chinese patients
por: Liu, Dong-yang, et al.
Publicado: (2018)

The effect of exhalation before the inhalation of dry powder aerosol drugs on the breathing parameters, emitted doses and aerosol size distributions
por: Farkas, Árpád, et al.
Publicado: (2023)

Functional respiratory imaging to assess the interaction between systemic roflumilast and inhaled ICS/LABA/LAMA
por: Vos, Wim, et al.
Publicado: (2016)

Effects of Roflumilast on Patients with Chronic Obstructive Pulmonary Disease Treated with Inhaled Corticosteroid/Long-Acting β2 Agonist: A Meta-analysis
por: Zeng, Shasha, et al.
Publicado: (2022)

Excipient Interactions in Glucagon Dry Powder Inhaler Formulation for Pulmonary Delivery
por: Rashid, Md Abdur, et al.
Publicado: (2019)

Puerarin dry powder inhaler formulations for pulmonary delivery: Development and characterization
por: Rashid, Md Abdur, et al.
Publicado: (2021)

Spray-Dried Powder Formulation of Capreomycin Designed for Inhaled Tuberculosis Therapy
por: Shao, Zitong, et al.
Publicado: (2021)

Progress on Thin Film Freezing Technology for Dry Powder Inhalation Formulations
por: Pardeshi, Sagar R., et al.
Publicado: (2022)

Knowledge and practice of dry powder inhalation among patients with chronic obstructive pulmonary disease in a regional hospital, Nepal
por: Baral, Mira Adhikari
Publicado: (2018)

Roflumilast: the evidence for its clinical potential in the treatment of chronic obstructive pulmonary disease
por: Wagner, Linda Timm, et al.
Publicado: (2005)

Optimization and Scale Up of Spray Dried CPZEN-45 Aerosol Powders for Inhaled Tuberculosis Treatment
por: Stewart, Ian E., et al.
Publicado: (2022)

Development and evaluation of Chitosan nanoparticles based dry powder inhalation formulations of Prothionamide
por: Debnath, Sujit Kumar, et al.
Publicado: (2018)

POxylated Dendrimer‐Based Nano‐in‐Micro Dry Powder Formulations for Inhalation Chemotherapy
por: Restani, Rita B., et al.
Publicado: (2018)

The Optimisation of Carrier Selection in Dry Powder Inhaler Formulation and the Role of Surface Energetics
por: Abiona, Olaitan, et al.
Publicado: (2022)

Inhalable microparticles as drug delivery systems to the lungs in a dry powder formulations
por: Knap, Karolina, et al.
Publicado: (2022)

Evaporation of sulfate aerosols at low relative humidity
por: Tsagkogeorgas, Georgios, et al.
Publicado: (2017)

Inhaled Edoxaban dry powder inhaler formulations: Development, characterization and their effects on the coagulopathy associated with COVID-19 infection
por: Rashid, Md Abdur, et al.
Publicado: (2021)

Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol
por: Calverley, Peter MA, et al.
Publicado: (2012)

Roflumilast in COPD: a Brazilian perspective
por: Stirbulov, Roberto, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_v856a4cpfve423fl6gqi6amnq1